Tema Etfs LLC Buys 17,469 Shares of CG Oncology, Inc. $CGON

Tema Etfs LLC increased its position in CG Oncology, Inc. (NASDAQ:CGON) by 61.1% in the 2nd quarter, HoldingsChannel reports. The fund owned 46,081 shares of the company’s stock after buying an additional 17,469 shares during the quarter. Tema Etfs LLC’s holdings in CG Oncology were worth $1,198,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of CGON. Winthrop Capital Management LLC purchased a new stake in CG Oncology in the 2nd quarter worth $38,000. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of CG Oncology by 15.6% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,945 shares of the company’s stock valued at $77,000 after acquiring an additional 398 shares in the last quarter. PNC Financial Services Group Inc. boosted its stake in shares of CG Oncology by 15.2% in the second quarter. PNC Financial Services Group Inc. now owns 3,279 shares of the company’s stock worth $85,000 after acquiring an additional 433 shares during the period. CWM LLC boosted its stake in shares of CG Oncology by 193.5% in the second quarter. CWM LLC now owns 6,193 shares of the company’s stock worth $161,000 after acquiring an additional 4,083 shares during the period. Finally, Federated Hermes Inc. boosted its stake in CG Oncology by 41.7% in the 1st quarter. Federated Hermes Inc. now owns 8,500 shares of the company’s stock worth $208,000 after purchasing an additional 2,500 shares during the period. 26.56% of the stock is currently owned by institutional investors.

Insider Transactions at CG Oncology

In other CG Oncology news, Director James Mulay sold 5,903 shares of the firm’s stock in a transaction dated Thursday, October 9th. The shares were sold at an average price of $43.99, for a total value of $259,672.97. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Brian Guan-Chyun Liu bought 1,515,151 shares of the company’s stock in a transaction on Thursday, September 11th. The shares were acquired at an average price of $33.00 per share, with a total value of $49,999,983.00. Following the transaction, the director directly owned 1,515,151 shares of the company’s stock, valued at approximately $49,999,983. This trade represents a ∞ increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last quarter, insiders sold 48,344 shares of company stock worth $1,921,431. 7.40% of the stock is currently owned by insiders.

CG Oncology Stock Performance

Shares of CG Oncology stock opened at $44.73 on Friday. The stock has a market cap of $3.61 billion, a price-to-earnings ratio of -21.93 and a beta of 1.29. The stock has a 50 day moving average price of $41.69 and a 200-day moving average price of $32.57. CG Oncology, Inc. has a one year low of $14.80 and a one year high of $45.94.

CG Oncology (NASDAQ:CGON) last released its quarterly earnings results on Friday, November 14th. The company reported ($0.57) earnings per share for the quarter, meeting the consensus estimate of ($0.57). The company had revenue of $0.16 million for the quarter, compared to analyst estimates of $0.07 million. CG Oncology had a negative return on equity of 21.67% and a negative net margin of 15,945.17%. Sell-side analysts predict that CG Oncology, Inc. will post -1.31 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on CGON shares. Royal Bank Of Canada upped their target price on shares of CG Oncology from $53.00 to $61.00 and gave the stock an “outperform” rating in a research report on Monday, November 17th. Weiss Ratings reiterated a “sell (d-)” rating on shares of CG Oncology in a research note on Wednesday, October 8th. Cantor Fitzgerald restated an “overweight” rating and set a $75.00 price objective on shares of CG Oncology in a research report on Monday, September 8th. Guggenheim began coverage on CG Oncology in a research note on Tuesday, October 7th. They issued a “buy” rating and a $90.00 price objective on the stock. Finally, Piper Sandler started coverage on CG Oncology in a research report on Monday, August 18th. They set an “overweight” rating and a $55.00 target price for the company. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $59.73.

CG Oncology Company Profile

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.